Pharmacological Management of Restless Legs Syndrome and Periodic Limb Movement Disorder in Children

Picchietti D, et al. Restless legs syndrome: prevalence and impact in children and adolescents–the Peds REST study. Pediatrics. 2007;120(2):253–66. Yilmaz K, et al. Prevalence and correlates of restless legs syndrome in adolescents. Dev Med Child Neurol. 2011;53(1):40–7. Turkdogan D, Bekiroglu N, Zaimoglu S. A prevalence study of restless legs syndrome in Turkish children and adolescents. Sleep Med. 2011;12(4):315–21. Walter LM, et al. Cardiovascular variability during periodic leg movements in sleep in children. Sleep. 2009;32(8):1093–9. Wing YK, et al. Periodic limb movement during sleep is associated with nocturnal hypertension in children. Sleep. 2010;33(6):759–65. Pagel JF, Forister N, Kwiatkowki C. Adolescent sleep disturbance and school performance: the confounding variable of socioeconomics. J Clin Sleep Med. 2007;3(1):19–23. Cortese S, et al. Restless legs syndrome and attention-deficit/hyperactivity disorder: a review of the literature. Sleep. 2005;28(8):1007–13. Stefansson H, et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med. 2007;357(7):639–47. Winkelmann J, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet. 2007;39(8):1000–6. Muhle H, et al. Childhood-onset restless legs syndrome: clinical and genetic features of 22 families. Mov Disord. 2008;23(8):1113–21 (quiz 1203). Pichler I, et al. Parkin gene modifies the effect of RLS4 on the age at onset of restless legs syndrome (RLS). Am J Med Genet Part B Neuropsychiatr Genet. 2010;153B(1):350–5. Brodeur C, et al. Treatment of restless legs syndrome and periodic movements during sleep with l-dopa: a double-blind, controlled study. Neurology. 1988;38(12):1845–8. Hening W, et al. The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep. 1999;22(7):970–99. Montplaisir J, et al. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology. 1999;52(5):938–43. Hornyak M, et al. Efficacy and safety of dopamine agonists in restless legs syndrome. Sleep Med. 2012;13(3):228–36. Clemens S, Rye D, Hochman S. Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective. Neurology. 2006;67(1):125–30. Ondo WG, Zhao HR, Le WD. Animal models of restless legs syndrome. Sleep Med. 2007;8(4):344–8. Staedt J, et al. Nocturnal myoclonus syndrome (periodic movements in sleep) related to central dopamine D2-receptor alteration. Eur Arch Psychiatry Clin Neurosci. 1995;245(1):8–10. Trenkwalder C, et al. Positron emission tomographic studies in restless legs syndrome. Mov Disord. 1999;14(1):141–5. Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology. 1999;52(5):932–7. Tribl GG, et al. Normal striatal D2 receptor binding in idiopathic restless legs syndrome with periodic leg movements in sleep. Nucl Med Commun. 2004;25(1):55–60. Walters AS, et al. Does the endogenous opiate system play a role in the Restless Legs Syndrome? A pilot post-mortem study. J Neurol Sci. 2009;279(1–2):62–5. Godau J, et al. Sonographic abnormalities of brainstem structures in restless legs syndrome. Sleep Med. 2008;9(7):782–9. Earley CJ, et al. Ferritin levels in the cerebrospinal fluid and restless legs syndrome: effects of different clinical phenotypes. Sleep. 2005;28(9):1069–75. Allen RP, et al. MRI measurement of brain iron in patients with restless legs syndrome. Neurology. 2001;56(2):263–5. Godau J, et al. Multiregional brain iron deficiency in restless legs syndrome. Mov Disord. 2008;23(8):1184–7. Kryger MH, Otake K, Foerster J. Low body stores of iron and restless legs syndrome: a correctable cause of insomnia in adolescents and teenagers. Sleep Med. 2002;3(2):127–32. Simakajornboon N, et al. Periodic limb movements in sleep and iron status in children. Sleep. 2003;26(6):735–8. Konofal E, et al. Impact of restless legs syndrome and iron deficiency on attention-deficit/hyperactivity disorder in children. Sleep Med. 2007;8(7–8):711–5. Allen RP, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4(2):101–19. Picchietti DL, et al. Pediatric restless legs syndrome diagnostic criteria: an update by the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14(12):1253–9. Littner MR, et al. Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep. 2004;27(3):557–9. Aurora RN, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep. 2012;35(8):1039–62. Ekbom K-A, Frey H. Restless legs: a clinical study of a hitherto overlooked disease in the legs characterized by peculiar paresthesia (“anxietas Tibiarum”), pain and weakness and occurring in two main forms, asthenia Crurum Paraesthetica and Asthenia Crurum Dolorosa: a short review of paresthesias in general. Ivar Hæggströms. 1945. Nordlander B. Restless legs. Br J Phys Med. 1954:160–162. Banerji N, Hurwitz L. Restless legs syndrome, with particular reference to its occurrence after gastric surgery. Br Med J. 1970;4(5738):774–5. Tings T, et al. Impact of regular LDL apheresis on the development of restless legs syndrome. Mov Disord. 2004;19(9):1072–5. Nagatsu T, Levitt M, Udenfriend S. Tyrosine hydroxylase the initial step in norepinephrine biosynthesis. J Biol Chem. 1964;239(9):2910–7. Earley CJ, et al. MRI-determined regional brain iron concentrations in early-and late-onset restless legs syndrome. Sleep Med. 2006;7(5):458–61. Li X, et al. Brain iron deficiency in idiopathic restless legs syndrome measured by quantitative magnetic susceptibility at 7 tesla. Sleep Med. 2016;22:75–82. Schmidauer C, et al. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann Neurol. 2005;58(4):630–4. Earley CJ, et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology. 2000;54(8):1698–700. Mizuno S, et al. CSF iron, ferritin and transferrin levels in restless legs syndrome. J Sleep Res. 2005;14(1):43–7. Connor JR, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology. 2003;61(3):304–9. Flowers CA, et al. A serum ferritin assay for prevalence studies of iron deficiency. Am J Hematol. 1986;23(2):141–51. Sun ER, et al. Iron and the Restless Legs Syndrome. Sleep. 1998;21(4):371–7. Guyatt GH, et al. Diagnosis of iron-deficiency anemia in the elderly. Am J Med. 1990;88(3):205–9. Silber MH, et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc. 2004;79(7):916–22. Hulthén L, et al. Effect of a mild infection on serum ferritin concentration—clinical and epidemiological implications. Eur J Clin Nutr. 1998;52(5):376–9. Grote L, et al. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov Disord. 2009;24(10):1445–52. Allen RP, et al. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med. 2011;12(9):906–13. Earley CJ, et al. A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med. 2009;10(2):206–11. Wang J, et al. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: a randomized, double-blind, placebo-controlled study. Sleep Med. 2009;10(9):973–5. Davis BJ, et al. A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome. Eur Neurol. 2000;43(2):70–5. Picchietti MA, Picchietti DL. Advances in pediatric restless legs syndrome: iron, genetics, diagnosis and treatment. Sleep Med. 2010;11(7):643–51. Mohri I, et al. Restless legs syndrome (RLS): an unrecognized cause for bedtime problems and insomnia in children. Sleep Med. 2008;9(6):701–2. Starn AL, Udall JN Jr. Iron deficiency anemia, pica, and restless legs syndrome in a teenage girl. Clin Pediatr. 2008;47(1):83–5. Mohri I, et al. Evaluation of oral iron treatment in pediatric restless legs syndrome (RLS). Sleep Med. 2012;13(4):429–32. Furudate N, et al. Daytime dysfunction in children with restless legs syndrome. J Neurol Sci. 2014;336(1–2):232–6. Grim K, et al. Treatment of childhood-onset restless legs syndrome and periodic limb movement disorder using intravenous iron sucrose. Sleep Med. 2013;14(11):1100–4. Dye TJ, Jain SV, Simakajornboon N. Outcomes of long-term iron supplementation in pediatric restless legs syndrome/periodic limb movement disorder (RLS/PLMD). Sleep Med. 2017;32:213–9. Winkelman JW, et al. Practice guideline summary: Treatment of restless legs syndrome in adults: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2016;87(24):2585–93. Walters AS, et al. Dopaminergic therapy in children with restless legs/periodic limb movements in sleep and ADHD. Dopaminergic Therapy Study Group. Pediatr Neurol. 2000;22(3):182–6. Kotagal S, Silber MH. Childhood-onset restless legs syndrome. Ann Neurol. 2004;56(6):803–7. Picchietti DL, Stevens HE. Early manifestations of restless legs syndrome in childhood and adolescence. Sleep Med. 2008;9(7):770–81. Guilleminault C, et al. Sleepwalking and sleep terrors in prepubertal children: what triggers them? Pediatrics. 2003;111(1):e17–25. Konofal E, et al. Ropinirole in a child with attention-deficit hyperactivity disorder and restless legs syndrome. Pediatr Neurol. 2005;32(5):350–1. Cortese S, Konofal E, Lecendreux M. Effectiveness of ropinirole for RLS and depressive symptoms in an 11-year-old girl. Sleep Med. 2009;10(2):259–61. Martinez S, Guilleminault C. Periodic leg movements in prepubertal children with sleep disturbance. Dev Med Child Neurol. 2004;46(11):765–70. Allen RP, Ritchie SY. Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset. Sleep Med. 2008;9(8):899–902. England SJ, et al. l-Dopa improves Restless Legs Syndrome and periodic limb movements in sleep but not attention-deficit-hyperactivity disorder in a double-blind trial in children. Sleep Med. 2011;12(5):471–7. Elshoff JP, Hudson J, Picchietti DL, Ridel K, Walters AS, Doggett K, Moran K, Oortiesen M, Ramirez F, Schollmayer E. Pharmacokinetics of rotigotine transdermal system in adolescents with idiopathic restless legs syndrome (Willis–Ekborn disease). Sleep Med. 2017;32:48–55. Tippmann-Peikert M, et al. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology. 2007;68(4):301–3. Schade R, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356(1):29–38. Gingras JL, Gaultney JF, Picchietti DL. Pediatric periodic limb movement disorder: sleep symptom and polysomnographic correlates compared to obstructive sleep apnea. J Clin Sleep Med. 2011;7(6):603-9A. Cundy KC, et al. XP13512 [(+/−)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther. 2004;311(1):324–33. Stewart BH, et al. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res. 1993;10(2):276–81. Garcia-Borreguero D, et al. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology. 2002;59(10):1573–9. Garcia-Borreguero D, et al. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology. 2010;74(23):1897–904. Allen R, et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med. 2010;11(6):512–9. Allen RP, et al. Comparison of pregabalin with pramipexole for Restless Legs Syndrome. N Engl J Med. 2014;370(7):621–31. Lee DO, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med. 2011;7(3):282–92. Bogan RK, et al. Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. Mayo Clin Proc. 2010;85(6):512–21. Winkelman JW, et al. Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. Mov Disord. 2011;26(11):2065–72. Amos LB, et al. Treatment of pediatric restless legs syndrome. Clin Pediatr (Phila). 2014;53(4):331–6. Khurana DS, et al. Efficacy of gabapentin therapy in children with refractory partial seizures. J Pediatr. 1996;128(6):829–33. Jan MMS, Zuberi SA, Alsaihati BA. Pregabalin: preliminary experience in intractable childhood epilepsy. Pediatr Neurol. 2009;40(5):347–50. Robinson AA, Malow BA. Gabapentin shows promise in treating refractory insomnia in children. J Child Neurol. 2013;28(12):1618–21. Vondracek P, et al. Efficacy of pregabalin in neuropathic pain in paediatric oncological patients. Eur J Paediatr Neurol. 2009;13(4):332–6. Boghen D, et al. The treatment of the restless legs syndrome with clonazepam: a prospective controlled study. Can J Neurol Sci. 1986;13(3):245–7. Montagna P, et al. Clonazepam and vibration in restless legs syndrome. Acta Neurol Scand. 1984;69(6):428–30. Saletu M, et al. Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): acute placebo-controlled sleep laboratory studies with clonazepam. Eur Neuropsychopharmacol. 2001;11(2):153–61. Newcorn JH, et al. Alpha 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children. Pediatr Clin N Am. 1998;45(5):1099–122 (viii). Wagner ML, et al. Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome. Sleep. 1996;19(1):52–8. Kaplan PW, et al. A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep. 1993;16(8):717–23. Walters AS, et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep. 1993;16(4):327–32. Lauerma H, Markkula J. Treatment of restless legs syndrome with tramadol: an open study. J Clin Psychiatry. 1999;60(4):241–4. Ondo WG. Methadone for refractory restless legs syndrome. Mov Disord. 2005;20(3):345–8. Walters AS, et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord. 2001;16(6):1105–9. Trenkwalder C, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 2013;12(12):1141–50. de Biase S, Valente M, Gigli GL. Intractable restless legs syndrome: role of prolonged-release oxycodone-naloxone. Neuropsychiatr Dis Treat. 2016;12:417–25. Kunz D, Bes F. Exogenous melatonin in periodic limb movement disorder: an open clinical trial and a hypothesis. Sleep. 2001;24(2):183–7. Whittom S, et al. Effects of melatonin and bright light administration on motor and sensory symptoms of RLS. Sleep Med. 2010;11(4):351–5. Balaban H, et al. Serum 25-hydroxyvitamin D levels in restless legs syndrome patients. Sleep Med. 2012;13(7):953–7. Oran M, et al. Possible association between vitamin D deficiency and restless legs syndrome. Neuropsychiatr Dis Treat. 2014;10:953–8. Wali S, et al. The effect of vitamin D supplements on the severity of restless legs syndrome. Sleep Breath. 2015;19(2):579–83. Qamar S, et al. Vitamin D levels in children with growing pains. J Coll Physicians Surg Pak. 2011;21(5):284–7. Galloway KS, Yaster M. Pain and symptom control in terminally ill children. Pediatr Clin N Am. 2000;47(3):711–46.